Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes.
null nullSteven J RussellRoy W BeckEdward R DamianoFiras H El-KhatibKatrina J RuedyCourtney A BalliroZoey LiPeter CalhounR Paul WadwaBruce BuckinghamKeren ZhouMark DanielsPhilip RaskinPerrin C WhiteJane LynchJeremy PettusIrl B HirschRobin GolandJohn B BuseDavida KrugerNelly MaurasAndrew MuirJanet B McGillFran CogenJill Weissberg-BenchellJordan S SherwoodLuz E CastellanosMallory A HillardMarwa TuffahaMelissa S PutmanMollie Y SandsGregory ForlenzaRobert SloverLaurel H MesserErin CobryViral N ShahSarit PolskyRayhan LalLaya EkhlaspourMichael S HughesMarina BasinaBetul HatipogluLeann OlanskyAmrit BhangooNikta ForghaniHimala KashmiriFrancoise SuttonAbha ChoudharyJimmy PennRabab JafriMaria RayasElia EscanameCatherine KerrRuby Favela-PrezasSchafer BoederSubbulaxmi TrikudanathanKristen M WilliamsNatasha LeibelM Sue KirkmanKate BergamoKlara R KleinJean M DostouSriram MachineniLaura A YoungJamie C DinerArti BhanJ Kimberly JonesMatthew BensonKeisha BirdKimberly EnglertJoe PermuyKristina CossenEric FelnerMaamoun SalamJulie M SilversteinSamantha AdamsonAndrea CedenoSeema MeighanAndrew DauberPublished in: The New England journal of medicine (2022)
In this 13-week, randomized trial involving adults and children with type 1 diabetes, use of a bionic pancreas was associated with a greater reduction than standard care in the glycated hemoglobin level. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; ClinicalTrials.gov number, NCT04200313.).